---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029500"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:54:04.766120+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma reports FY2023 net loss of $42.4M, focuses on GTX-104 Phase 3

## Summary
- Net loss of $42.4M ($0.95 loss per share) vs $9.8M loss prior year; impairments of $33.5M.
- Cash, cash equivalents and short-term investments $27.9M, expected to fund through Q2 2025 for potential NDA filing.
- FDA confirmed 505(b)(2) pathway for GTX-104; Phase 3 Safety Study protocol submitted, first patient H2 2023.
- Strategic realignment: R&D focus solely on GTX-104, evaluating partnerships for GTX-102/GTX-101.
- R&D expenses $9.9M (up 77% YoY); G&A expenses reduced to $7.6M; restructuring with layoffs in Canada.

## SEC filing metadata
- accession: 0000950170-23-029500
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/0000950170-23-029500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/acst-20230623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029500
- JSON: https://secwatch.observer/filing/0000950170-23-029500.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029500.txt

## Key facts
- Earnings Releases
  Grace Therapeutics, Inc. reported the fiscal year ended March 31, 2023 results: net income $(42.4) million, EPS $(0.95) loss per share.
  - Period: the fiscal year ended March 31, 2023
  - Net income: $(42.4) million
  - EPS: $(0.95) loss per share
  - Result: reported results
  source text: Net loss and total comprehensive loss for the twelve months ended March 31, 2023 was $(42.4) million, or $(0.95) loss per share, compared to a net loss of $(9.8) million, or $(0.27) income per share, for the twelve months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/0000950170-23-029500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.